- Nearly 14% of women with epithelial ovarian cancer undergoing primary debulking surgery (PDS) develop venous thromboembolism (VTE) within 6 months.
Why this matters
- Guidelines do not recommend VTE prophylaxis during outpatient, ambulatory chemotherapy in patients with solid tumors.
- 888 women with epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer underwent PDS.
- Primary outcome: VTE within 6 months.
- Funding: None disclosed.
- 3.2% of patients had VTE within 30 days of surgery.
- Among 860 women without an immediate history of a VTE, the cumulative incidence of VTE at 30 days and 6 months was 7.5% and 13.8%, respectively.
- Independent risk factors for diagnosis of VTE within 6 months:
- macroscopic vs microscopic residual disease (aHR, 1.99; 95% CI, 1.35-2.94),
- increasing estimated blood loss per doubling (aHR, 1.25; 95% CI, 1.05-1.49),
- longer hospital length of stay (aHR, 3.00; 95% CI, 1.57-5.75), and
- cardiac event within 30 days (aHR, 2.75; 95% CI, 1.56-4.80).
- There were no differences in the risk for VTE within the first 30 days and 6 months between different VTE prophylaxes.
- Patients with recurrent disease and those who received neoadjuvant chemotherapy were not included.